Autoinjectors Market by Type (Devices, Finished Formulation), Usage (Disposable, Reusable), Actuation Mechanism (Mechanical, Electronic), Therapy (Rheumatoid Arthritis, Obesity, Diabetes), ROA (SC, IM), Volume (< 3ml, > 3ml) - Global Forecast to 2031

1 INTRODUCTION 48 1.1 STUDY OBJECTIVES 48 1.2 MARKET DEFINITION 48 1.3 STUDY SCOPE 49 1.3.1 SEGMENTS CONSIDERED 49 1.3.2 INCLUSIONS & EXCLUSIONS 50 1.3.3 YEARS CONSIDERED 51 1.3.4 CURRENCY CONSIDERED 51 1.4 STAKEHOLDERS 52 1.5 SUMMARY OF CHANGES 52 2 EXECUTIVE SUMMARY 54 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 54 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 56 2.3 DISRUPTIVE TRENDS IN AUTOINJECTORS MARKET 58 2.4 HIGH-GROWTH SEGMENTS 58 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 60 3 PREMIUM INSIGHTS 62 3.1 AUTOINJECTORS MARKET OVERVIEW 62 3.2 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY AND USAGE 63 3.3 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY AND ACTUATION MECHANISM 64 3.4 GEOGRAPHIC SNAPSHOT OF AUTOINJECTOR DEVICES MARKET 65 3.5 GEOGRAPHIC SNAPSHOT OF FINISHED FORMULATION AUTOINJECTORS MARKET 66 4 MARKET OVERVIEW 67 4.1 INTRODUCTION 67 4.2 MARKET DYNAMICS 67 4.2.1 DRIVERS 68 4.2.1.1 Rising prevalence of chronic and autoimmune diseases 68 4.2.1.2 Increasing regulatory approvals for autoinjectors 68 4.2.1.3 High demand for biosimilars and biologics 69 4.2.1.4 Growing adoption of self-administered medicines 70 4.2.1.5 Government support and favorable reimbursement policies 71 4.2.2 RESTRAINTS 72 4.2.2.1 Focus on needle-free drug delivery systems and prevalence of needle phobia 72   4.2.3 OPPORTUNITIES 72 4.2.3.1 Impending patent expiry of biological molecules 72 4.2.3.2 Launch of technologically advanced autoinjectors 74 4.2.3.3 Untapped opportunities in emerging markets 74 4.2.4 CHALLENGES 75 4.2.4.1 Development of autoinjectors for multiple drug viscosities 75 4.2.4.2 Risk of device malfunctions and recalls 75 4.3 UNMET NEEDS AND WHITE SPACES 75 4.3.1 UNMET NEEDS IN AUTOINJECTORS MARKET 75 4.3.2 WHITE SPACE OPPORTUNITIES 76 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 76 4.4.1 INTERCONNECTED MARKETS 76 4.4.2 CROSS-SECTOR OPPORTUNITIES 77 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 77 5 INDUSTRY TRENDS 79 5.1 PORTER’S FIVE FORCES ANALYSIS 79 5.1.1 THREAT OF NEW ENTRANTS 80 5.1.2 THREAT OF SUBSTITUTES 80 5.1.3 BARGAINING POWER OF SUPPLIERS 81 5.1.4 BARGAINING POWER OF BUYERS 81 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 81 5.2 MACROECONOMIC OUTLOOK 82 5.2.1 INTRODUCTION 82 5.2.2 GDP TRENDS AND FORECAST 82 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 83 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 83 5.3 SUPPLY CHAIN ANALYSIS 84 5.4 VALUE CHAIN ANALYSIS 85 5.5 MARKET ECOSYSTEM 86 5.5.1 AUTOINJECTORS MARKET PROVIDERS 86 5.5.2 END USERS 88 5.5.3 REGULATORY BODIES 88 5.6 PRICING ANALYSIS 89 5.6.1 AVERAGE SELLING PRICE, BY KEY PLAYER, 2025 (USD) 89 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 90 5.6.2.1 Rheumatoid arthritis 90 5.6.2.2 Anaphylaxis 90 5.6.2.3 Diabetes 90 5.6.2.4 Obesity 91   5.7 TRADE ANALYSIS 92 5.7.1 IMPORT DATA FOR HS CODE 901890 92 5.7.2 EXPORT DATA FOR HS CODE 901890 93 5.8 REIMBURSEMENT SCENARIO 93 5.8.1 KEY CONFERENCES & EVENTS (2025–2026) 94 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 95 5.10 INVESTMENT & FUNDING SCENARIO 96 5.11 CASE STUDY ANALYSIS 97 5.12 IMPACT OF US TARIFFS—AUTOINJECTORS MARKET 98 5.12.1 INTRODUCTION 98 5.12.2 KEY TARIFF RATES 99 5.12.3 PRICE IMPACT ANALYSIS 99 5.12.4 IMPACT ON COUNTRIES/REGIONS 100 5.12.4.1 North America 100 5.12.4.2 Asia Pacific 100 5.12.4.3 Europe 101 5.12.4.4 Latin America 102 5.12.5 IMPACT ON END-USE SEGMENTS 102 5.13 DEVICES FOR LARGE-VOLUME FORMULATIONS 103 5.14 DEVICES FOR HIGHLY VISCOUS FORMULATIONS 103 5.15 INSIGHTS ON FUTURE AREAS OF FOCUS IN AUTOINJECTORS MARKET 106 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 107 6.1 KEY EMERGING TECHNOLOGIES 107 6.1.1 INJECTION MECHANISM TECHNOLOGY 107 6.1.2 ELECTRONIC AND CONNECTIVITY SOLUTIONS 107 6.2 COMPLEMENTARY TECHNOLOGIES 108 6.2.1 POWER ASSISTANCE MECHANISMS 108 6.2.2 ADVANCED NEEDLE TECHNOLOGY 108 6.2.3 DRUG CONTAINER AND CARTRIDGE TECHNOLOGIES 109 6.3 ADJACENT TECHNOLOGIES 109 6.3.1 WEARABLE DRUG DELIVERY DEVICES 109 6.3.2 IMPLANTABLE DRUG DELIVERY SYSTEMS 109 6.3.3 NEEDLE-FREE INJECTION TECHNOLOGY 110 6.4 TECHNOLOGY/PRODUCT ROADMAP 110 6.4.1 NEAR TERM (2025-2027) 110 6.4.2 MID-TERM (2028-2030) 110 6.4.3 LONG TERM (2030+) 111 6.5 PATENT ANALYSIS 111 6.5.1 JURISDICTION AND TOP APPLICANT ANALYSIS 111 6.6 FUTURE APPLICATIONS 115 6.6.1 AI-ENABLED PERSONALIZED DRUG DELIVERY 115 6.6.2 COMBINATION THERAPY DELIVERY 115 6.6.3 REUSABLE AUTOINJECTOR PLATFORMS 116 6.7 IMPACT OF AI/GEN AI ON AUTOINJECTORS MARKET 116 6.7.1 INTRODUCTION 116 6.7.2 TOP USE CASES AND MARKET POTENTIAL 116 6.7.3 BEST PRACTICES FOLLOWED BY MANUFACTURERS/OEMS IN AUTOINJECTORS MARKET 118 7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 120 7.1 DECISION-MAKING PROCESS 120 7.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 120 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 121 7.2.2 BUYING CRITERIA 122 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 123 7.4 UNMET NEEDS OF VARIOUS END-USE INDUSTRIES 123 7.5 MARKET PROFITABILITY 124 8 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 125 8.1 REGIONAL REGULATIONS AND COMPLIANCE 125 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125 8.1.2 REGULATORY FRAMEWORK 127 8.1.2.1 North America 127 8.1.2.2 Europe 128 8.1.2.3 Asia Pacific 128 8.1.2.4 Latin America 129 8.1.2.5 Middle East & Africa 129 8.1.3 CERTIFICATIONS, LABELING, ECO-STANDARDS 129 8.1.4 INDUSTRY STANDARDS 129 8.2 SUSTAINABILITY INITIATIVES 130 8.2.1 REUSABLE AUTOINJECTOR PLATFORMS 130 8.2.2 USE OF BIO-BASED POLYMERS 130 8.2.3 CIRCULAR DEVICE DESIGN AND RECYCLABILITY 130 9 AUTOINJECTORS MARKET, BY TYPE 131 9.1 INTRODUCTION 132 9.2 FINISHED FORMULATION AUTOINJECTORS 132 9.2.1 READY-TO-USE DESIGN AND PATIENT CONVENIENCE DRIVE MARKET LEADERSHIP 132   9.3 AUTOINJECTOR DEVICES 134 9.3.1 FLEXIBILITY AND PLATFORM-BASED INTEGRATION SUPPORT MARKET ADOPTION 134 10 AUTOINJECTORS MARKET, BY USAGE 136 10.1 INTRODUCTION 137 10.2 DISPOSABLE AUTOINJECTORS 138 10.2.1 EASE OF USE AND REDUCED RISK OF NEEDLESTICK INJURIES TO PROPEL MARKET GROWTH 138 10.3 REUSABLE AUTOINJECTORS 141 10.3.1 COST-EFFECTIVENESS, ADAPTABILITY, AND SUSTAINABILITY TO DRIVE MARKET EXPANSION 141 11 AUTOINJECTORS MARKET, BY ACTUATION MECHANISM 144 11.1 INTRODUCTION 145 11.2 MECHANICAL (SPRING-BASED) AUTOINJECTORS 146 11.2.1 USER-FRIENDLY DESIGN AND INCREASED PATIENT CONTROL TO AUGMENT MARKET GROWTH 146 11.3 ELECTRONIC AUTOINJECTORS 149 11.3.1 EASE OF ACCURATE DOCUMENTATION AND COMPREHENSIVE PATIENT RECORDS TO SUPPORT MARKET GROWTH 149 12 AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION 152 12.1 INTRODUCTION 153 12.2 SUBCUTANEOUS ADMINISTRATION 154 12.2.1 EASE OF USE, RAPID ABSORPTION, AND SUITABILITY FOR SELF-ADMINISTRATION TO AID MARKET GROWTH 154 12.3 INTRAMUSCULAR ADMINISTRATION 157 12.3.1 NEED FOR PRECISE DOSE DELIVERY IN EMERGENCY CLINICAL SETTINGS TO DRIVE MARKET 157 13 AUTOINJECTORS MARKET, BY THERAPY AREA 160 13.1 INTRODUCTION 161 13.2 RHEUMATOID ARTHRITIS 162 13.2.1 HIGH DISEASE PREVALENCE AND NEED FOR FREQUENT DOSING TO DRIVE MARKET 162 13.3 DIABETES 164 13.3.1 LARGE DIABETIC POPULATION AND EASE OF ADMINISTRATION TO STIMULATE DEMAND 164 13.4 ANAPHYLAXIS 166 13.4.1 REQUIREMENT FOR PROMPT INITIAL TREATMENT FOR PATIENTS WITH FOOD ALLERGIES TO FUEL MARKET GROWTH 166 13.5 MULTIPLE SCLEROSIS 167 13.5.1 AVAILABILITY OF COST-EFFECTIVE GENERIC ORAL MULTIPLE SCLEROSIS DRUGS TO LIMIT MARKET GROWTH 167   13.6 OBESITY 169 13.6.1 INCREASING FOCUS ON WEIGHT MANAGEMENT TO BOOST MARKET GROWTH 169 13.7 OTHER THERAPY AREAS 170 14 AUTOINJECTORS MARKET, BY DRUG TYPE 172 14.1 INTRODUCTION 173 14.2 BIOLOGICS 174 14.2.1 INCREASING USE IN INJECTABLE THERAPIES AND SELF-ADMINISTRATION TO DRIVE MARKET 174 14.3 BIOSIMILARS 177 14.3.1 COST-EFFECTIVE ALTERNATIVES ACCELERATING MARKET EXPANSION 177 14.4 SMALL MOLECULES 180 14.4.1 CRITICAL ROLE IN SELECTIVE INJECTABLES AND EMERGENCY USE CASES 180 15 AUTOINJECTORS MARKET, BY VOLUME 183 15.1 INTRODUCTION 184 15.2 UP TO 3ML 185 15.2.1 RISING PREVALENCE OF AUTOIMMUNE DISORDERS AND LONG-TERM CHRONIC DISEASES TO PROPEL MARKET GROWTH 185 15.3 ABOVE 3ML 188 15.3.1 INCREASING FOCUS ON COMPLEX TREATMENTS WITH HIGH-VISCOSITY DRUGS TO DRIVE THE MARKET 188 16 AUTOINJECTORS MARKET, BY END USER 191 16.1 AUTOINJECTOR DEVICE END USERS 192 16.1.1 PHARMACEUTICAL & BIOTECH COMPANIES 192 16.1.1.1 Expanding pipelines, advancements, and rising patient adherence to propel market 192 16.1.2 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 194 16.1.2.1 Growing trend of outsourcing and demand for specialized drug-device manufacturing capabilities support growth 194 16.2 FINISHED FORMULATION AUTOINJECTOR END USERS 195 16.2.1 HOME CARE SETTINGS 195 16.2.1.1 Cost-effectiveness and increased availability of home care support services to propel market growth 195 16.2.2 HOSPITALS & CLINICS 197 16.2.2.1 Technological advancements and availability of real-time patient data to support market growth 197 16.2.3 AMBULATORY CARE CENTERS 198 16.2.3.1 Growing demand for outpatient services to fuel market growth 198 16.2.4 OTHER END USERS 199   17 AUTOINJECTORS MARKET, BY REGION 201 17.1 INTRODUCTION 202 17.2 NORTH AMERICA 203 17.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 203 17.2.2 US 213 17.2.2.1 US holds largest share in North American 213 17.2.3 CANADA 219 17.2.3.1 Aging population and increasing prevalence of allergies to propel market growth 219 17.3 EUROPE 224 17.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 224 17.3.2 GERMANY 232 17.3.2.1 Growing investments and increasing government spending on healthcare to drive market 232 17.3.3 UK 238 17.3.3.1 Increase in prevalence of lifestyle diseases and allergies supports demand growth 238 17.3.4 FRANCE 243 17.3.4.1 Favorable reimbursement policies and increased investment to drive market growth 243 17.3.5 ITALY 249 17.3.5.1 Rising elderly population pool to drive the market 249 17.3.6 SPAIN 254 17.3.6.1 Favorable reimbursement scenario and prevalence of chronic disease 254 17.3.7 NETHERLANDS 260 17.3.7.1 Strong healthcare system and aging population drive market growth 260 17.3.8 REST OF EUROPE 265 17.4 ASIA PACIFIC 270 17.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 270 17.4.2 JAPAN 280 17.4.2.1 High healthcare expenditure, favorable reimbursement, and insurance coverage to support market growth 280 17.4.3 CHINA 286 17.4.3.1 Increase in prevalence of lifestyle diseases and allergies drives market growth 286 17.4.4 INDIA 291 17.4.4.1 Increasing burden of diabetes and cardiovascular diseases to spur market growth 291 17.4.5 AUSTRALIA 297 17.4.5.1 Growing older population and rising prevalence of target diseases to propel market 297 17.4.6 SOUTH KOREA 302 17.4.6.1 Rising obesity and chronic disease burden propel market growth 302 17.4.7 THAILAND 307 17.4.7.1 Rising geriatric population and chronic disease burden driving autoinjectors market growth 307 17.4.8 VIETNAM 313 17.4.8.1 Aging population and healthcare expansion aiding autoinjectors market growth in Vietnam 313 17.4.9 REST OF ASIA PACIFIC 318 17.5 LATIN AMERICA 323 17.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 323 17.5.2 BRAZIL 331 17.5.2.1 Rising obesity to stimulate market growth 331 17.5.3 MEXICO 336 17.5.3.1 Rising disease burden to support market growth 336 17.5.4 REST OF LATIN AMERICA 342 17.6 MIDDLE EAST & AFRICA 347 17.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 347 17.6.2 GCC COUNTRIES 355 17.6.2.1 Kingdom of Saudi Arabia (KSA) 361 17.6.2.1.1 Strong public investments and rising trend of home care to propel market 361 17.6.2.2 United Arab Emirates 367 17.6.2.2.1 Favorable government strategies for health and infrastructure driving market growth 367 17.6.2.3 Other GCC Countries 372 17.6.3 REST OF MIDDLE EAST & AFRICA 377 18 COMPETITIVE LANDSCAPE 383 18.1 INTRODUCTION 383 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2026 383 18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AUTOINJECTORS MARKET 384 18.3 REVENUE ANALYSIS, 2023–2025 388 18.3.1 REVENUE ANALYSIS: AUTOINJECTOR DEVICES MARKET 388 18.3.2 REVENUE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET 389 18.4 MARKET SHARE ANALYSIS, 2025 389 18.4.1 MARKET SHARE ANALYSIS: AUTOINJECTOR DEVICES MARKET 389 18.4.2 MARKET SHARE ANALYSIS: FINISHED FORMULATION AUTOINJECTORS MARKET 392 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 395 18.5.1 AUTOINJECTOR DEVICES MARKET 395 18.5.1.1 Stars 395 18.5.1.2 Emerging leaders 395 18.5.1.3 Pervasive players 395 18.5.1.4 Participants 396 18.5.1.5 Company footprint: key players, 2025 397 18.5.1.5.1 Company footprint 397 18.5.1.5.2 Region footprint 398 18.5.1.5.3 Usage footprint 399 18.5.1.5.4 Volume footprint 400 18.5.1.5.5 Route of administration footprint 401 18.5.2 FINISHED FORMULATION AUTOINJECTORS MARKET 402 18.5.2.1 Stars 402 18.5.2.2 Emerging leaders 402 18.5.2.3 Pervasive players 402 18.5.2.4 Participants 402 18.5.2.5 Company footprint: key players, 2025 404 18.5.2.5.1 Company footprint 404 18.5.2.5.2 Region footprint 404 18.5.2.5.3 Usage footprint 405 18.5.2.5.4 Volume footprint 405 18.5.2.5.5 Route of administration footprint 406 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 406 18.6.1 AUTOINJECTOR DEVICES MARKET 406 18.6.1.1 Progressive companies 406 18.6.1.2 Responsive companies 406 18.6.1.3 Dynamic companies 406 18.6.1.4 Starting blocks 406 18.6.1.5 Competitive benchmarking: Startups/SMEs, 2025 408 18.6.1.6 Competitive benchmarking of key startup/SME players 409 18.6.2 FINISHED FORMULATION AUTOINJECTORS MARKET 409 18.6.2.1 Progressive companies 409 18.6.2.2 Responsive companies 409 18.6.2.3 Dynamic companies 409 18.6.2.4 Starting blocks 409 18.6.2.5 Competitive benchmarking: startups/SMEs, 2025 411 18.6.2.6 Competitive benchmarking of key startup/SME players 411 18.7 COMPANY VALUATION AND FINANCIAL METRICS 412 18.7.1 FINANCIAL METRICS 412 18.7.2 COMPANY VALUATION 412 18.8 BRAND COMPARISON 413 18.9 COMPETITIVE SCENARIO 414 18.9.1 PRODUCT LAUNCHES & APPROVALS 414 18.9.2 DEALS 415 18.9.3 EXPANSIONS 416 18.9.4 PRODUCT LAUNCHES & APPROVALS 416 18.9.5 DEALS 418 18.9.6 EXPANSIONS 418 19 COMPANY PROFILES 419 19.1 KEY PLAYERS: AUTOINJECTOR DEVICES MARKET 419 19.1.1 SHL MEDICAL AG 419 19.1.1.1 Business overview 419 19.1.1.2 Products offered 419 19.1.1.3 Recent developments 420 19.1.1.3.1 Product launches 420 19.1.1.3.2 Deals 421 19.1.1.3.3 Expansions 423 19.1.1.4 MnM view 423 19.1.1.4.1 Key strengths 423 19.1.1.4.2 Strategic choices 424 19.1.1.4.3 Weaknesses and competitive threats 424 19.1.2 YPSOMED AG 425 19.1.2.1 Business overview 425 19.1.2.2 Products offered 427 19.1.2.3 Recent developments 428 19.1.2.3.1 Product launches 428 19.1.2.3.2 Deals 428 19.1.2.3.3 Expansions 430 19.1.2.4 MnM view 430 19.1.2.4.1 Key strengths 430 19.1.2.4.2 Strategic choices 430 19.1.2.4.3 Weaknesses and competitive threats 431 19.1.3 WEST PHARMACEUTICAL SERVICES, INC. 432 19.1.3.1 Business overview 432 19.1.3.2 Products offered 433 19.1.3.3 Recent developments 434 19.1.3.3.1 Expansions 434 19.1.3.4 MnM view 434 19.1.3.4.1 Key strengths 434 19.1.3.4.2 Strategic choices 434 19.1.3.4.3 Weaknesses and competitive threats 434 19.1.4 BECTON, DICKINSON AND COMPANY (BD) 435 19.1.4.1 Business overview 435 19.1.4.2 Products offered 436 19.1.4.3 Recent developments 437 19.1.4.3.1 Deals 437 19.1.4.4 MnM view 437 19.1.4.4.1 Key strengths 437 19.1.4.4.2 Strategic choices 437 19.1.4.4.3 Weaknesses and competitive threats 438 19.1.5 PHILLIPS-MEDISIZE 439 19.1.5.1 Business overview 439 19.1.5.2 Products offered 439 19.1.5.3 Recent developments 440 19.1.5.3.1 Expansions 440 19.1.6 HALOZYME, INC. 441 19.1.6.1 Business overview 441 19.1.6.2 Products offered 442 19.1.7 OWEN MUMFORD 443 19.1.7.1 Business overview 443 19.1.7.2 Products offered 443 19.1.7.3 Recent developments 444 19.1.7.3.1 Product launches 444 19.1.7.3.2 Deals 444 19.2 KEY PLAYERS: FINISHED FORMULATION AUTOINJECTORS MARKET 445 19.2.1 ELI LILLY AND COMPANY 445 19.2.1.1 Business overview 445 19.2.1.2 Products offered 446 19.2.1.3 Recent developments 447 19.2.1.3.1 Product approvals 447 19.2.1.3.2 Deals 448 19.2.1.3.3 Expansions 449 19.2.1.4 MnM view 450 19.2.1.4.1 Key strengths 450 19.2.1.4.2 Strategic choices 450 19.2.1.4.3 Weaknesses and competitive threats 450 19.2.2 ABBVIE INC. 451 19.2.2.1 Business overview 451 19.2.2.2 Products offered 452 19.2.2.3 Recent developments 453 19.2.2.3.1 Product approvals 453 19.2.2.3.2 Deals 454 19.2.2.4 MnM view 454 19.2.2.4.1 Key strengths 454 19.2.2.4.2 Strategic choices 454 19.2.2.4.3 Weaknesses and competitive threats 454 19.2.3 SANOFI 455 19.2.3.1 Business overview 455 19.2.3.2 Products offered 456 19.2.3.3 Recent developments 457 19.2.3.3.1 Product approvals 457 19.2.3.4 MnM view 457 19.2.3.4.1 Key strengths 457 19.2.3.4.2 Strategic choices 457 19.2.3.4.3 Weaknesses and competitive threats 457 19.2.4 NOVO NORDISK A/S 458 19.2.4.1 Business overview 458 19.2.4.2 Products offered 459 19.2.4.3 Recent developments 460 19.2.4.3.1 Product approvals 460 19.2.4.3.2 Deals 461 19.2.4.3.3 Expansions 461 19.2.4.3.4 Other developments 462 19.2.5 AMGEN INC. 463 19.2.5.1 Business overview 463 19.2.5.2 Products offered 464 19.2.5.3 Recent developments 465 19.2.5.3.1 Product launches 465 19.2.5.3.2 Expansions 466 19.2.5.3.3 Other developments 466 19.2.6 JOHNSON & JOHNSON 467 19.2.6.1 Business overview 467 19.2.6.2 Products offered 468 19.2.6.3 Recent developments 469 19.2.6.3.1 Product approvals 469 19.2.6.3.2 Other developments 469 19.2.7 GSK PLC 470 19.2.7.1 Business overview 470 19.2.7.2 Products offered 471 19.2.7.3 Recent developments 472 19.2.7.3.1 Product approvals 472 19.2.8 ASTRAZENECA 473 19.2.8.1 Business overview 473 19.2.8.2 Products offered 474 19.2.8.3 Recent developments 475 19.2.8.3.1 Product approvals 475 19.2.8.3.2 Deals 475 19.2.8.3.3 Expansions 476 19.2.8.3.4 Other developments 476   19.3 OTHER PLAYERS 477 19.3.1 GERRESHEIMER AG 477 19.3.2 HASELMEIER GMBH 477 19.3.3 SMC LTD 478 19.3.4 KALEO, INC. 478 19.3.5 SOLTEAM INCORPORATION CO., LTD. 479 19.3.6 ELCAM DRUG DELIVERY DEVICES 480 19.3.7 CROSSJECT 481 19.3.8 JABIL, INC. 481 19.3.9 CONGRUENCE MEDICAL SOLUTIONS LLC 482 19.3.10 MIDAS PHARMA GMBH 482 19.3.11 XERIS PHARMACEUTICALS, INC. 483 19.3.12 WINDGAP MEDICAL, INC 483 19.3.13 ALTAVIZ 484 20 RESEARCH METHODOLOGY 485 20.1 RESEARCH DATA 485 20.2 RESEARCH METHODOLOGY DESIGN 485 20.2.1 SECONDARY DATA 486 20.2.1.1 Key data from secondary sources 487 20.2.2 PRIMARY DATA 488 20.2.2.1 Key industry insights 489 20.3 MARKET SIZE ESTIMATION: AUTOINJECTOR DEVICES 491 20.4 MARKET SIZE ESTIMATION: FINISHED FORMULATIONS 493 20.4.1 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 496 20.5 MARKET GROWTH RATE PROJECTIONS 497 20.6 DATA TRIANGULATION 500 20.7 MARKET SHARE ANALYSIS 501 20.8 RESEARCH ASSUMPTIONS 501 20.8.1 GROWTH RATE ASSUMPTIONS 502 20.9 RISK ASSESSMENT 503 20.10 LIMITATIONS 503 20.10.1 METHODOLOGY-RELATED LIMITATIONS 503 20.10.2 SCOPE-RELATED LIMITATIONS 503 20.11 RISK ANALYSIS 504   21 APPENDIX 505 21.1 DISCUSSION GUIDE 505 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 514 21.3 CUSTOMIZATION OPTIONS 516 21.3.1 COMPANY INFORMATION 516 21.3.2 GEOGRAPHIC ANALYSIS 516 21.3.3 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 516 21.3.4 COUNTRY-LEVEL VOLUME ANALYSIS 516 21.3.5 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 516 21.4 RELATED REPORTS 517 21.5 AUTHOR DETAILS 518

TABLE 1 AUTOINJECTORS MARKET: INCLUSIONS & EXCLUSIONS 50 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 51 TABLE 3 RECENT APPROVALS OF AUTOINJECTOR BIOLOGICS, 2023–2025 69 TABLE 4 PATENT EXPIRY OF KEY BIOLOGICS 73 TABLE 5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS IN AUTOINJECTOR DEVICES MARKET 77 TABLE 6 AUTOINJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 79 TABLE 7 GDP CHANGE, BY KEY COUNTRIES, 2021-2030, IN USD BILLION 82 TABLE 8 LIST OF KEY AUTOINJECTOR DEVICE PROVIDERS 87 TABLE 9 LIST OF KEY FINISHED FORMULATION PRODUCT PROVIDERS 87 TABLE 10 LIST OF KEY END USERS 88 TABLE 11 LIST OF KEY REGULATORY BODIES 88 TABLE 12 AVERAGE SELLING PRICE OF FINISHED FORMULATION AUTOINJECTORS, BY KEY PLAYER, 2025 (USD) 89 TABLE 13 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR RHEUMATOID ARTHRITIS, BY REGION, 2023–2025 (USD) 90 TABLE 14 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR ANAPHYLAXIS, BY REGION, 2023–2025 (USD) 90 TABLE 15 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR DIABETES, BY REGION, 2023–2025 (USD) 90 TABLE 16 AVERAGE SELLING PRICE TREND OF FINISHED FORMULATION AUTOINJECTORS FOR OBESITY BY REGION, 2023–2025 (USD) 91 TABLE 17 AVERAGE SELLING PRICE OF 0F AUTOINJECTOR DEVICES FOR DISPOSABLE AND REUSABLE AUTOINJECTORS, BY KEY PLAYER, 2025 (USD) 91 TABLE 18 AVERAGE SELLING PRICE TREND 0F DISPOSABLE AUTOINJECTORS, BY REGION, 2023–2025, (USD) 92 TABLE 19 AVERAGE SELLING PRICE TREND 0F REUSABLE AUTOINJECTORS, BY REGION, 2023–2025, (USD) 92 TABLE 20 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY, 2021–2025 (USD THOUSAND) 92 TABLE 21 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN MEDICAL, SURGICAL, OR VETERINARY SCIENCES (HS CODE 901890), BY COUNTRY, 2021–2025 (USD THOUSAND) 93 TABLE 22 AUTOINJECTORS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 94 TABLE 23 CASE STUDY 1: MERCK KGAA'S REBISMART SMART MEDICATION MANAGEMENT 97 TABLE 24 CASE STUDY 2: USB’S CIMZIA AUTOCLICKS ENHANCING AUTOINJECTORS USABILITY 97 TABLE 25 CASE STUDY 3: PRODUCT DEVELOPMENT SUPPORT FOR REUSABLE AUTOINJECTORS 98 TABLE 26 US ADJUSTED RECIPROCAL TARIFF RATES, 2024 99 TABLE 27 KEY PRODUCT-RELATED TARIFF EFFECTIVE 99 TABLE 28 NORTH AMERICA: IMPACT OF US TARIFF ON CANADA 100 TABLE 29 ASIA PACIFIC: IMPACT OF US TARIFFS ON CHINA, JAPAN, AND INDIA 100 TABLE 30 EUROPE: IMPACT OF US TARIFFS ON GERMANY AND UK 101 TABLE 31 LATIN AMERICA: IMPACT OF US TARIFFS ON MEXICO 102 TABLE 32 AUTOINJECTORS MARKET: DEVICES FOR LARGE-VOLUME FORMULATIONS 103 TABLE 33 AUTOINJECTORS MARKET: DEVICES FOR HIGHLY VISCOUS FORMULATIONS 104 TABLE 34 FORMULATION AND DEVICE TECHNOLOGIES ENABLING SUBCUTANEOUS DELIVERY OF HIGH-DOSE BIOLOGICS 104 TABLE 35 AUTOINJECTORS MARKET: KEY PATENTS, 2023–2025 113 TABLE 36 BEST PRACTICES FOLLOWED BY MANUFACTURERS/OEMS 119 TABLE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF AUTOINJECTORS 121 TABLE 38 KEY BUYING CRITERIA FOR AUTOINJECTORS, BY END USER 122 TABLE 39 ADOPTION BARRIERS & INTERNAL CHALLENGES IN AUTOINJECTORS MARKET 123 TABLE 40 UNMET NEEDS OF VARIOUS END-USE INDUSTRIES IN AUTOINJECTORS MARKET 123 TABLE 41 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125 TABLE 42 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125 TABLE 43 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 126 TABLE 44 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 127 TABLE 45 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 127 TABLE 46 AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132 TABLE 47 AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 132 TABLE 48 COMMERCIALLY AVAILABLE FINISHED FORMULATION AUTOINJECTORS 133 TABLE 49 FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 50 COMMERCIALLY AVAILABLE AUTOINJECTOR DEVICES 134 TABLE 51 AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 52 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 137 TABLE 53 AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 137 TABLE 54 FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 137 TABLE 55 FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 138 TABLE 56 COMMERCIALLY AVAILABLE DISPOSABLE AUTOINJECTORS 138 TABLE 57 DISPOSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 58 DISPOSABLE FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 59 COMMERCIALLY AVAILABLE REUSABLE AUTOINJECTORS 141 TABLE 60 REUSABLE AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 61 REUSABLE FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 62 AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 145 TABLE 63 AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 145 TABLE 64 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 146 TABLE 65 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 146 TABLE 66 COMMERCIALLY AVAILABLE MECHANICAL (SPRING-BASED) AUTOINJECTORS 147 TABLE 67 MECHANICAL (SPRING-BASED) AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 68 MECHANICAL (SPRING-BASED) FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 69 COMMERCIALLY AVAILABLE ELECTRONIC AUTOINJECTORS 149 TABLE 70 ELECTRONIC AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 71 ELECTRONIC FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 72 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 153 TABLE 73 AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 153 TABLE 74 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 153 TABLE 75 FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 154 TABLE 76 COMMERCIALLY AVAILABLE AUTOINJECTORS USING THE SUBCUTANEOUS ROUTE 155 TABLE 77 AUTOINJECTOR DEVICES MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 78 FINISHED FORMULATION AUTOINJECTORS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 79 COMMERCIALLY AVAILABLE AUTOINJECTORS USING THE INTRAMUSCULAR ROUTE 157 TABLE 80 AUTOINJECTOR DEVICES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 81 FINISHED FORMULATION AUTOINJECTORS MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 82 AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 161 TABLE 83 AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 161 TABLE 84 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR RHEUMATOID ARTHRITIS 162 TABLE 85 AUTOINJECTORS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 86 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR DIABETES 164 TABLE 87 AUTOINJECTORS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 88 AUTOINJECTORS MARKET FOR ANAPHYLAXIS, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 89 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR MULTIPLE SCLEROSIS 167 TABLE 90 AUTOINJECTORS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 91 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR OBESITY 169 TABLE 92 AUTOINJECTORS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 93 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR OTHER THERAPY AREAS 170 TABLE 94 AUTOINJECTORS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 95 AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 173 TABLE 96 AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (THOUSAND UNITS) 173 TABLE 97 FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 174 TABLE 98 FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (THOUSAND UNITS) 174 TABLE 99 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR BIOLOGICS 175 TABLE 100 AUTOINJECTOR DEVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 101 FINISHED FORMULATION AUTOINJECTORS MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 102 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR BIOSIMILARS 177 TABLE 103 AUTOINJECTOR DEVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 104 FINISHED FORMULATION AUTOINJECTORS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 105 COMMERCIALLY AVAILABLE AUTOINJECTORS FOR SMALL MOLECULES 180 TABLE 106 AUTOINJECTOR DEVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 107 FINISHED FORMULATION AUTOINJECTORS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 108 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 184 TABLE 109 AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 184 TABLE 110 FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 184 TABLE 111 FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 185 TABLE 112 COMMERCIALLY AVAILABLE AUTOINJECTORS: UP TO 3ML 186 TABLE 113 UP TO 3ML AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 114 UP TO 3ML FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 115 COMMERCIALLY AVAILABLE AUTOINJECTORS: ABOVE 3ML 188 TABLE 116 ABOVE 3ML AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 117 ABOVE 3ML FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 118 AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 192 TABLE 119 AUTOINJECTOR DEVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 120 AUTOINJECTOR DEVICES MARKET FOR CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 121 FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 195 TABLE 122 FINISHED FORMULATION AUTOINJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 123 FINISHED FORMULATION AUTOINJECTORS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 124 FINISHED FORMULATION AUTOINJECTORS MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 125 FINISHED FORMULATION AUTOINJECTORS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 126 AUTOINJECTOR DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 202 TABLE 127 FINISHED FORMULATION AUTOINJECTORS MARKET, BY REGION, 2024–2031 (USD MILLION) 202 TABLE 128 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 129 NORTH AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 130 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 206 TABLE 131 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 206 TABLE 132 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 207 TABLE 133 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 207 TABLE 134 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 207 TABLE 135 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 208 TABLE 136 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 208 TABLE 137 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 208 TABLE 138 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 209 TABLE 139 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 209 TABLE 140 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 141 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 210 TABLE 142 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 210 TABLE 143 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 210 TABLE 144 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 211 TABLE 145 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 211 TABLE 146 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 212 TABLE 147 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 212 TABLE 148 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 149 AUTOINJECTORS APPROVED BY US FDA, 2018–2024 213 TABLE 150 US: KEY MACROINDICATORS 214 TABLE 151 US: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 152 US: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 214 TABLE 153 US: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 215 TABLE 154 US: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 215 TABLE 155 US: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 215 TABLE 156 US: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 216 TABLE 157 US: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 216 TABLE 158 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 216 TABLE 159 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 217 TABLE 160 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 217 TABLE 161 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 217 TABLE 162 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 218 TABLE 163 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 218 TABLE 164 US: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 165 CANADA: KEY MACROINDICATORS 219 TABLE 166 CANADA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 167 CANADA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 220 TABLE 168 CANADA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 220 TABLE 169 CANADA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 220 TABLE 170 CANADA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 221 TABLE 171 CANADA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 221 TABLE 172 CANADA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 221 TABLE 173 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 222 TABLE 174 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 222 TABLE 175 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 222 TABLE 176 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 223 TABLE 177 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 223 TABLE 178 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 223 TABLE 179 CANADA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 224 TABLE 180 EUROPE: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 181 EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 182 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 225 TABLE 183 EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 226 TABLE 184 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 226 TABLE 185 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 226 TABLE 186 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 227 TABLE 187 EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 227 TABLE 188 EUROPE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 227 TABLE 189 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 228 TABLE 190 EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 228 TABLE 191 EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 228 TABLE 192 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 193 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 229 TABLE 194 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 229 TABLE 195 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 230 TABLE 196 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 230 TABLE 197 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 231 TABLE 198 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 231 TABLE 199 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 231 TABLE 200 EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 232 TABLE 201 GERMANY: KEY MACROINDICATORS 233 TABLE 202 GERMANY: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 203 GERMANY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 233 TABLE 204 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 234 TABLE 205 GERMANY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 234 TABLE 206 GERMANY: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 234 TABLE 207 GERMANY: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 235 TABLE 208 GERMANY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 235 TABLE 209 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 235 TABLE 210 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 236 TABLE 211 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 236 TABLE 212 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 236 TABLE 213 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 237 TABLE 214 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 237 TABLE 215 GERMANY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 216 UK: KEY MACROINDICATORS 238 TABLE 217 UK: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 218 UK: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 239 TABLE 219 UK: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 239 TABLE 220 UK: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 240 TABLE 221 UK: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 240 TABLE 222 UK: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 240 TABLE 223 UK: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 241 TABLE 224 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 241 TABLE 225 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 241 TABLE 226 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 242 TABLE 227 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 242 TABLE 228 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 242 TABLE 229 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 243 TABLE 230 UK: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 231 FRANCE: KEY MACROINDICATORS 244 TABLE 232 FRANCE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 233 FRANCE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 244 TABLE 234 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 245 TABLE 235 FRANCE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 245 TABLE 236 FRANCE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 245 TABLE 237 FRANCE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 246 TABLE 238 FRANCE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 239 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 246 TABLE 240 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 247 TABLE 241 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 247 TABLE 242 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 247 TABLE 243 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 248 TABLE 244 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 248 TABLE 245 FRANCE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 246 ITALY: KEY MACROINDICATORS 249 TABLE 247 ITALY: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 248 ITALY: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 250 TABLE 249 ITALY: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 250 TABLE 250 ITALY: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 250 TABLE 251 ITALY: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 251 TABLE 252 ITALY: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 251 TABLE 253 ITALY: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 254 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 252 TABLE 255 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 252 TABLE 256 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 252 TABLE 257 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 253 TABLE 258 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 253 TABLE 259 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 253 TABLE 260 ITALY: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 261 SPAIN: KEY MACROINDICATORS 255 TABLE 262 SPAIN: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 263 SPAIN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 255 TABLE 264 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 256 TABLE 265 SPAIN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 256 TABLE 266 SPAIN: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 256 TABLE 267 SPAIN: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 257 TABLE 268 SPAIN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 269 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 257 TABLE 270 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 258 TABLE 271 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 258 TABLE 272 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 258 TABLE 273 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 259 TABLE 274 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 259 TABLE 275 SPAIN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 276 NETHERLANDS: KEY MACROINDICATORS 260 TABLE 277 NETHERLANDS: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 278 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 261 TABLE 279 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 261 TABLE 280 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 261 TABLE 281 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 262 TABLE 282 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 262 TABLE 283 NETHERLANDS: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 262 TABLE 284 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 263 TABLE 285 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 263 TABLE 286 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263 TABLE 287 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 264 TABLE 288 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 264 TABLE 289 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 264 TABLE 290 NETHERLANDS: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 265 TABLE 291 REST OF EUROPE: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 292 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 266 TABLE 293 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 266 TABLE 294 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266 TABLE 295 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 267 TABLE 296 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 267 TABLE 297 REST OF EUROPE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 298 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 268 TABLE 299 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 268 TABLE 300 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268 TABLE 301 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 269 TABLE 302 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 269 TABLE 303 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 269 TABLE 304 REST OF EUROPE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 270 TABLE 305 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273 TABLE 306 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 307 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 273 TABLE 308 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 274 TABLE 309 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 274 TABLE 310 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 274 TABLE 311 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 275 TABLE 312 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 275 TABLE 313 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 275 TABLE 314 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 276 TABLE 315 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD THOUSAND UNITS 276 TABLE 316 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 276 TABLE 317 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277 TABLE 318 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 277 TABLE 319 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 277 TABLE 320 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 278 TABLE 321 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 278 TABLE 322 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 279 TABLE 323 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 279 TABLE 324 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 280 TABLE 325 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 326 JAPAN: KEY MACROINDICATORS 281 TABLE 327 JAPAN: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 328 JAPAN: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 282 TABLE 329 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 282 TABLE 330 JAPAN: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 282 TABLE 331 JAPAN: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 283 TABLE 332 JAPAN: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 283 TABLE 333 JAPAN: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 334 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 284 TABLE 335 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 284 TABLE 336 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 284 TABLE 337 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 285 TABLE 338 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 285 TABLE 339 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 285 TABLE 340 JAPAN: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 286 TABLE 341 CHINA: KEY MACROINDICATORS 286 TABLE 342 CHINA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 343 CHINA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 287 TABLE 344 CHINA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 287 TABLE 345 CHINA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 288 TABLE 346 CHINA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 288 TABLE 347 CHINA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 288 TABLE 348 CHINA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 289 TABLE 349 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 289 TABLE 350 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 289 TABLE 351 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 290 TABLE 352 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 290 TABLE 353 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 290 TABLE 354 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 291 TABLE 355 CHINA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 291 TABLE 356 INDIA: KEY MACROINDICATORS 292 TABLE 357 INDIA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 358 INDIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 292 TABLE 359 INDIA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 293 TABLE 360 INDIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 293 TABLE 361 INDIA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 293 TABLE 362 INDIA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 294 TABLE 363 INDIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 294 TABLE 364 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 294 TABLE 365 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 295 TABLE 366 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 295 TABLE 367 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 295 TABLE 368 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 296 TABLE 369 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 296 TABLE 370 INDIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 296 TABLE 371 AUSTRALIA: KEY MACROINDICATORS 297 TABLE 372 AUSTRALIA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 373 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 298 TABLE 374 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 298 TABLE 375 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 298 TABLE 376 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 299 TABLE 377 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 299 TABLE 378 AUSTRALIA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 299 TABLE 379 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 300 TABLE 380 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 300 TABLE 381 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 300 TABLE 382 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 301 TABLE 383 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 301 TABLE 384 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 301 TABLE 385 AUSTRALIA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 302 TABLE 386 SOUTH KOREA: KEY MACROINDICATORS 302 TABLE 387 SOUTH KOREA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 388 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 303 TABLE 389 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 303 TABLE 390 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 304 TABLE 391 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 304 TABLE 392 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 304 TABLE 393 SOUTH KOREA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 305 TABLE 394 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 305 TABLE 395 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 305 TABLE 396 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 306 TABLE 397 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 306 TABLE 398 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 306 TABLE 399 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 307 TABLE 400 SOUTH KOREA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 307 TABLE 401 THAILAND: KEY MACROINDICATORS 308 TABLE 402 THAILAND: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 403 THAILAND: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 308 TABLE 404 THAILAND: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 309 TABLE 405 THAILAND: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 309 TABLE 406 THAILAND: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 309 TABLE 407 THAILAND: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 310 TABLE 408 THAILAND: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 310 TABLE 409 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 310 TABLE 410 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 311 TABLE 411 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 311 TABLE 412 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 311 TABLE 413 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 312 TABLE 414 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 312 TABLE 415 THAILAND: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 416 VIETNAM: KEY MACROINDICATORS 313 TABLE 417 VIETNAM: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 418 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 314 TABLE 419 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 314 TABLE 420 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 314 TABLE 421 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 315 TABLE 422 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 315 TABLE 423 VIETNAM: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 315 TABLE 424 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 316 TABLE 425 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 316 TABLE 426 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 316 TABLE 427 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 317 TABLE 428 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 317 TABLE 429 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 317 TABLE 430 VIETNAM: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 431 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 432 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 319 TABLE 433 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 319 TABLE 434 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 319 TABLE 435 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 320 TABLE 436 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 320 TABLE 437 REST OF ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 320 TABLE 438 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 321 TABLE 439 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 321 TABLE 440 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 321 TABLE 441 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 322 TABLE 442 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 322 TABLE 443 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 322 TABLE 444 REST OF ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 323 TABLE 445 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 324 TABLE 446 LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 447 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 324 TABLE 448 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 325 TABLE 449 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 325 TABLE 450 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 325 TABLE 451 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 326 TABLE 452 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 326 TABLE 453 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 326 TABLE 454 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 327 TABLE 455 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 327 TABLE 456 LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 327 TABLE 457 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 328 TABLE 458 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 328 TABLE 459 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 328 TABLE 460 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 329 TABLE 461 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 329 TABLE 462 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 330 TABLE 463 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 330 TABLE 464 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 330 TABLE 465 LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 331 TABLE 466 BRAZIL: MACROECONOMIC INDICATORS 331 TABLE 467 BRAZIL: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 468 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 332 TABLE 469 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 332 TABLE 470 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 333 TABLE 471 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 333 TABLE 472 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 333 TABLE 473 BRAZIL: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 334 TABLE 474 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 334 TABLE 475 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 334 TABLE 476 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 335 TABLE 477 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 335 TABLE 478 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 335 TABLE 479 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 336 TABLE 480 BRAZIL: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 336 TABLE 481 MEXICO: MACROECONOMIC INDICATORS 337 TABLE 482 MEXICO: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 483 MEXICO: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 337 TABLE 484 MEXICO: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 338 TABLE 485 MEXICO: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 338 TABLE 486 MEXICO: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 338 TABLE 487 MEXICO: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 339 TABLE 488 MEXICO: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 339 TABLE 489 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 339 TABLE 490 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 340 TABLE 491 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 340 TABLE 492 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 340 TABLE 493 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 341 TABLE 494 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 341 TABLE 495 MEXICO: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 341 TABLE 496 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 497 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 342 TABLE 498 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 343 TABLE 499 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 343 TABLE 500 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 343 TABLE 501 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 344 TABLE 502 REST OF LATIN AMERICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 344 TABLE 503 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 344 TABLE 504 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 345 TABLE 505 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 345 TABLE 506 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 345 TABLE 507 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 346 TABLE 508 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 346 TABLE 509 REST OF LATIN AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 510 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 348 TABLE 511 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 348 TABLE 512 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 348 TABLE 513 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (THOUSAND UNITS) 349 TABLE 514 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 349 TABLE 515 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (THOUSAND UNITS) 349 TABLE 516 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 350 TABLE 517 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (THOUSAND UNITS) 350 TABLE 518 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 350 TABLE 519 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 351 TABLE 520 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (THOUSAND UNITS) 351 TABLE 521 MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 351 TABLE 522 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY REGION, 2024–2031 (USD MILLION) 352 TABLE 523 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 352 TABLE 524 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 352 TABLE 525 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 353 TABLE 526 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 353 TABLE 527 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (THOUSAND UNITS) 354 TABLE 528 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 354 TABLE 529 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 354 TABLE 530 MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 355 TABLE 531 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 356 TABLE 532 GCC COUNTRIES: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 533 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 356 TABLE 534 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 357 TABLE 535 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 357 TABLE 536 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 357 TABLE 537 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 358 TABLE 538 GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 358 TABLE 539 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 358 TABLE 540 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 359 TABLE 541 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 359 TABLE 542 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 359 TABLE 543 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 360 TABLE 544 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 360 TABLE 545 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 360 TABLE 546 GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 361 TABLE 547 KSA: KEY MACROINDICATORS 362 TABLE 548 KSA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 549 KSA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 362 TABLE 550 KSA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 363 TABLE 551 KSA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 363 TABLE 552 KSA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 363 TABLE 553 KSA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 364 TABLE 554 KSA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 364 TABLE 555 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 364 TABLE 556 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 365 TABLE 557 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 365 TABLE 558 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 365 TABLE 559 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 366 TABLE 560 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 366 TABLE 561 KSA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 366 TABLE 562 UNITED ARAB EMIRATES: KEY MACROINDICATORS 367 TABLE 563 UNITED ARAB EMIRATES: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 564 UAE: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 368 TABLE 565 UAE: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 368 TABLE 566 UAE: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 368 TABLE 567 UAE: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 369 TABLE 568 UAE: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 369 TABLE 569 UAE: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 369 TABLE 570 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 370 TABLE 571 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 370 TABLE 572 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 370 TABLE 573 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 371 TABLE 574 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 371 TABLE 575 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 371 TABLE 576 UAE: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 372 TABLE 577 OTHER GCC COUNTRIES: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 372 TABLE 578 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 373 TABLE 579 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 373 TABLE 580 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 373 TABLE 581 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 374 TABLE 582 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 374 TABLE 583 OTHER GCC COUNTRIES: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 374 TABLE 584 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 375 TABLE 585 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 375 TABLE 586 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 375 TABLE 587 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 376 TABLE 588 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 376 TABLE 589 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 376 TABLE 590 OTHER GCC COUNTRIES: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 377 TABLE 591 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 592 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY USAGE, 2024–2031 (USD MILLION) 378 TABLE 593 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 378 TABLE 594 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 379 TABLE 595 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 379 TABLE 596 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY VOLUME, 2024–2031 (USD MILLION) 379 TABLE 597 REST OF MIDDLE EAST & AFRICA: AUTOINJECTOR DEVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 380 TABLE 598 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY USAGE, 2024–2031 (USD MILLION) 380 TABLE 599 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ACTUATION MECHANISM, 2024–2031 (USD MILLION) 380 TABLE 600 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 381 TABLE 601 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY THERAPY AREA, 2024–2031 (USD MILLION) 381 TABLE 602 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY DRUG TYPE, 2024–2031 (USD MILLION) 381 TABLE 603 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY VOLUME, 2024–2031 (USD MILLION) 382 TABLE 604 REST OF MIDDLE EAST & AFRICA: FINISHED FORMULATION AUTOINJECTORS MARKET, BY END USER, 2024–2031 (USD MILLION) 382 TABLE 605 OVERVIEW OF STRATEGIES DEPLOYED BY KEY AUTOINJECTOR DEVICE MANUFACTURING COMPANIES, JANUARY 2022–FEBRUARY 2026 384 TABLE 606 OVERVIEW OF STRATEGIES DEPLOYED BY KEY FINISHED FORMULATION AUTOINJECTORS COMPANIES, JANUARY 2022–FEBRUARY 2026 386 TABLE 607 AUTOINJECTOR DEVICES MARKET: DEGREE OF COMPETITION 390 TABLE 608 FINISHED FORMULATION AUTOINJECTORS MARKET: DEGREE OF COMPETITION 393 TABLE 609 AUTOINJECTOR DEVICES MARKET: REGION FOOTPRINT 398 TABLE 610 AUTOINJECTOR DEVICES MARKET: USAGE FOOTPRINT 399 TABLE 611 AUTOINJECTOR DEVICES MARKET: VOLUME FOOTPRINT 400 TABLE 612 AUTOINJECTOR DEVICES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 401 TABLE 613 FINISHED FORMULATION AUTOINJECTORS MARKET: REGION FOOTPRINT 404 TABLE 614 FINISHED FORMULATION AUTOINJECTORS MARKET: USAGE FOOTPRINT 405 TABLE 615 FINISHED FORMULATION AUTOINJECTORS MARKET: VOLUME FOOTPRINT 405 TABLE 616 FINISHED FORMULATION AUTOINJECTORS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 406 TABLE 617 AUTOINJECTOR DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 408 TABLE 618 AUTOINJECTOR DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 409 TABLE 619 FINISHED FORMULATION AUTOINJECTORS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 411 TABLE 620 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 411 TABLE 621 AUTOINJECTOR DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–FEBRUARY 2026 414 TABLE 622 AUTOINJECTOR DEVICES MARKET: DEALS, JANUARY 2022–FEBRUARY 2026 415 TABLE 623 AUTOINJECTOR DEVICES MARKET: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 416 TABLE 624 FINISHED FORMULATION AUTOINJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–FEBRUARY 2026 416 TABLE 625 FINISHED FORMULATION AUTOINJECTORS MARKET: DEALS, JANUARY 2022–FEBRUARY 2026 418 TABLE 626 FINISHED FORMULATION AUTOINJECTORS MARKET: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 418 TABLE 627 SHL MEDICAL AG: COMPANY OVERVIEW 419 TABLE 628 SHL MEDICAL AG: PRODUCTS OFFERED 419 TABLE 629 SHL MEDICAL AG: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024 420 TABLE 630 SHL MEDICAL AG: DEALS, JANUARY 2021–JULY 2024 421 TABLE 631 SHL MEDICAL AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024 423 TABLE 632 YPSOMED AG: COMPANY OVERVIEW 425 TABLE 633 YPSOMED AG: PRODUCTS OFFERED 427 TABLE 634 YPSOMED AG: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 428 TABLE 635 YPSOMED AG: DEALS, JANUARY 2022–FEBRUARY 2026 428 TABLE 636 YPSOMED AG: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 430 TABLE 637 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 432 TABLE 638 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 433 TABLE 639 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 434 TABLE 640 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 435 TABLE 641 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 436 TABLE 642 BECTON, DICKINSON AND COMPANY (BD): DEALS, JANUARY 2022–FEBRUARY 2026 437 TABLE 643 PHILLIPS-MEDISIZE: COMPANY OVERVIEW 439 TABLE 644 PHILLIPS-MEDISIZE: PRODUCTS OFFERED 439 TABLE 645 PHILLIPS-MEDISIZE: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 440 TABLE 646 HALOZYME, INC.: COMPANY OVERVIEW 441 TABLE 647 HALOZYME, INC.: PRODUCTS OFFERED 442 TABLE 648 OWEN MUMFORD: COMPANY OVERVIEW 443 TABLE 649 OWEN MUMFORD: PRODUCTS OFFERED 443 TABLE 650 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 444 TABLE 651 OWEN MUMFORD LTD.: DEALS, JANUARY 2022–FEBRUARY 2026 444 TABLE 652 ELI LILLY AND COMPANY: COMPANY OVERVIEW 445 TABLE 653 ELI LILLY AND COMPANY: PRODUCTS OFFERED 446 TABLE 654 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 447 TABLE 655 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–FEBRUARY 2026 448 TABLE 656 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 449 TABLE 657 ABBVIE INC.: COMPANY OVERVIEW 451 TABLE 658 ABBVIE INC.: PRODUCTS OFFERED 452 TABLE 659 ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 453 TABLE 660 ABBVIE INC.: DEALS, JANUARY 2022–FEBRUARY 2026 454 TABLE 661 SANOFI: COMPANY OVERVIEW 455 TABLE 662 SANOFI: PRODUCTS OFFERED 456 TABLE 663 SANOFI: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 457 TABLE 664 NOVO NORDISK A/S: COMPANY OVERVIEW 458 TABLE 665 NOVO NORDISK A/S: PRODUCTS OFFERED 459 TABLE 666 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 460 TABLE 667 NOVO NORDISK A/S: DEALS, JANUARY 2022–FEBRUARY 2026 461 TABLE 668 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 461 TABLE 669 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 462 TABLE 670 AMGEN INC.: COMPANY OVERVIEW 463 TABLE 671 AMGEN INC.: PRODUCTS OFFERED 464 TABLE 672 AMGEN INC.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 465 TABLE 673 AMGEN INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 466 TABLE 674 AMGEN INC.: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 466 TABLE 675 JOHNSON & JOHNSON: COMPANY OVERVIEW 467 TABLE 676 JOHNSON & JOHNSON: PRODUCTS OFFERED 468 TABLE 677 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 469 TABLE 678 JOHNSON & JOHNSON: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024 469 TABLE 679 GSK PLC: COMPANY OVERVIEW 470 TABLE 680 GSK PLC: PRODUCTS OFFERED 471 TABLE 681 GSK PLC: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 472 TABLE 682 ASTRAZENECA: COMPANY OVERVIEW 473 TABLE 683 ASTRAZENECA: PRODUCTS OFFERED 474 TABLE 684 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2022–FEBRUARY 2026 475 TABLE 685 ASTRAZENECA: DEALS, JANUARY 2022–FEBRUARY 2026 475 TABLE 686 ASTRAZENECA: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 476 TABLE 687 ASTRAZENECA: OTHER DEVELOPMENTS, JANUARY 2022–FEBRUARY 2026 476 TABLE 688 GERRESHEIMER AG: COMPANY OVERVIEW 477 TABLE 689 HASELMEIER GMBH: COMPANY OVERVIEW 477 TABLE 690 SMC LTD: COMPANY OVERVIEW 478 TABLE 691 KALEO, INC.: COMPANY OVERVIEW 478 TABLE 692 SOLTEAM INCORPORATION CO., LTD.: COMPANY OVERVIEW 479 TABLE 693 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW 480 TABLE 694 CROSSJECT: COMPANY OVERVIEW 481 TABLE 695 JABIL, INC.: COMPANY OVERVIEW 481 TABLE 696 CONGRUENCE MEDICAL SOLUTIONS LLC: COMPANY OVERVIEW 482 TABLE 697 MIDAS PHARMA GMBH: COMPANY OVERVIEW 482 TABLE 698 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 483 TABLE 699 WINDGAP MEDICAL, INC: COMPANY OVERVIEW 483 TABLE 700 ALTAVIZ: COMPANY OVERVIEW 484 TABLE 701 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON AUTOINJECTORS MARKET 499 TABLE 702 RISK ASSESSMENT: AUTOINJECTORS MARKET 503 FIGURE 1 AUTOINJECTORS MARKET: SEGMENTS CONSIDERED 49 FIGURE 2 AUTOINJECTORS MARKET: YEARS CONSIDERED 51 FIGURE 3 MARKET SCENARIO 54 FIGURE 4 AUTOINJECTOR DEVICES MARKET, 2024–2031 55 FIGURE 5 FINISHED FORMULATION AUTOINJECTORS MARKET, 2024–2031 55 FIGURE 6 AUTOINJECTOR DEVICES: MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2022–2025 56 FIGURE 7 FINISHED FORMULATIONS: MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2022–2025 57 FIGURE 8 DISRUPTIONS INFLUENCING GROWTH OF AUTOINJECTORS MARKET 58 FIGURE 9 HIGH-GROWTH SEGMENTS IN AUTOINJECTOR DEVICES MARKET, 2026–2031 58 FIGURE 10 HIGH-GROWTH SEGMENTS IN FINISHED FORMULATIONS MARKET, 2026–2031 59 FIGURE 11 DEVICES: ASIA PACIFIC TO REGISTER HIGHEST CAGR, IN TERMS OF VALUE, DURING FORECAST PERIOD 60 FIGURE 12 FINISHED FORMULATIONS: ASIA PACIFIC TO REGISTER HIGHEST CAGR, IN TERMS OF VALUE, DURING FORECAST PERIOD 61 FIGURE 13 GROWING INCIDENCE OF CHRONIC DISEASES AND PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH 62 FIGURE 14 DISPOSABLE AUTOINJECTORS SEGMENT IN ASIA PACIFIC ACCOUNTED FOR LARGEST SHARE IN 2025 63 FIGURE 15 MECHANICAL AUTOINJECTORS SEGMENT IN ASIA PACIFIC REGION ACCOUNTED FOR THE LARGEST SHARE IN 2025 64 FIGURE 16 CHINA TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 65 FIGURE 17 CHINA TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 66 FIGURE 18 AUTOINJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67 FIGURE 19 AUTOINJECTORS MARKET: PORTER'S FIVE FORCES ANALYSIS 80 FIGURE 20 AUTOINJECTORS MARKET EQUIPMENT MARKET: SUPPLY CHAIN ANALYSIS 84 FIGURE 21 AUTOINJECTORS MARKET: VALUE CHAIN ANALYSIS 85 FIGURE 22 AUTOINJECTORS MARKET ECOSYSTEM 86 FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 95 FIGURE 24 INVESTMENT AND FUNDING SCENARIO FOR AUTOINJECTORS MARKET PLAYERS 96 FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR AUTOINJECTOR PATENTS (JANUARY 2014–MARCH 2026) 112 FIGURE 26 AUTOINJECTORS MARKET: AI USE CASES 118 FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AUTOINJECTORS 121 FIGURE 28 KEY BUYING CRITERIA FOR AUTOINJECTORS, BY END USER 122 FIGURE 29 NORTH AMERICA: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2025) 204 FIGURE 30 NORTH AMERICA: FINISHED FORMULATION AUTOINJECTORS MARKET SNAPSHOT (2025) 205 FIGURE 31 ASIA PACIFIC: AUTOINJECTOR DEVICES MARKET SNAPSHOT (2025) 271 FIGURE 32 ASIA PACIFIC: FINISHED FORMULATION AUTOINJECTORS MARKET SNAPSHOT (2025) 272 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2022–2025) 388 FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2023–2025) 389 FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2025) 390 FIGURE 36 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2025) 391 FIGURE 37 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTOR DEVICES MARKET (2025) 391 FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 393 FIGURE 39 US: MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 394 FIGURE 40 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS IN FINISHED FORMULATION AUTOINJECTORS MARKET (2025) 394 FIGURE 41 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 396 FIGURE 42 AUTOINJECTOR DEVICES MARKET: COMPANY FOOTPRINT 397 FIGURE 43 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 403 FIGURE 44 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY FOOTPRINT 404 FIGURE 45 AUTOINJECTOR DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 407 FIGURE 46 FINISHED FORMULATION AUTOINJECTORS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 410 FIGURE 47 EV/EBITDA OF KEY VENDORS 412 FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 412 FIGURE 49 AUTOINJECTOR DEVICES MARKET: BRAND COMPARATIVE ANALYSIS 413 FIGURE 50 YPSOMED AG: COMPANY SNAPSHOT (2025) 426 FIGURE 51 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2025) 433 FIGURE 52 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025) 436 FIGURE 53 HALOZYME, INC.: COMPANY SNAPSHOT (2025) 442 FIGURE 54 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 446 FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2025) 452 FIGURE 56 SANOFI: COMPANY SNAPSHOT (2025) 456 FIGURE 57 NOVO NORDISK A/S: COMPANY SNAPSHOT (2025) 459 FIGURE 58 AMGEN INC.: COMPANY SNAPSHOT (2025) 464 FIGURE 59 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2025) 468 FIGURE 60 GSK PLC: COMPANY SNAPSHOT (2025) 471 FIGURE 61 ASTRAZENECA: COMPANY SNAPSHOT (2025) 474 FIGURE 62 AUTOINJECTORS MARKET: RESEARCH DESIGN 485 FIGURE 63 PRIMARY SOURCES 488 FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 489 FIGURE 65 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (DEMAND SIDE) 490 FIGURE 66 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 490 FIGURE 67 AUTOINJECTOR DEVICES MARKET: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 491 FIGURE 68 MARKET SIZE ESTIMATION FOR AUTOINJECTOR DEVICES: REVENUE SHARE ANALYSIS 492 FIGURE 69 ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS (2025) 492 FIGURE 70 GLOBAL MARKET ESTIMATION: SUPPLY-SIDE ANALYSIS (BOTTOM-UP APPROACH) 493 FIGURE 71 MARKET SIZE ESTIMATION FOR FINISHED FORMULATIONS: REVENUE SHARE ANALYSIS 494 FIGURE 72 ILLUSTRATIVE EXAMPLE OF ABBVIE INC.: REVENUE SHARE ANALYSIS (2025) 495 FIGURE 73 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 496 FIGURE 74 AUTOINJECTOR DEVICES MARKET: CAGR PROJECTIONS (2026–2031) 498 FIGURE 75 FINISHED FORMULATION AUTOINJECTORS MARKET: CAGR PROJECTIONS (2026–2031) 498 FIGURE 76 DATA TRIANGULATION METHODOLOGY 500